Simon Chandler

CEO • Rinri Therapeutics

Simon has deep sector knowledge and in-depth experience of the biotech sector and a strong understanding of the advanced therapeutics landscape having spent most of his career within the blue-chip companies in the biotechnology and pharmaceutical industries. Simon joins Rinri Therapeutics from IP Group plc. the specialist early-stage technology venture capital firm where he worked to identify transformative, world-leading investment opportunities from partner University IP portfolios and to then work in tandem with founder teams to build exciting early-stage spin-out technology companies. This included broad exposure to the life science market across AI-diagnostics, medical devices, oesteogenesis, synthetic biology and anti-virals. He was attracted to Rinri by the high calibre nature of the research findings with early but compelling preclinical data showing dramatic restoration of hearing in ontological disease models that clearly demonstrated the potential for the technology to make a real-world impact on patients and healthcare systems. This all made Rinri an exciting prospect to build a pioneering early-stage biotechnology company. Simon received his BSc. (Hons.) from Leeds University and holds a Ph.D. in Molecular Biology and Biochemistry from the University of York and holds CIM qualifications.

Also speaking

Michael Delahaye

Director, Team Leader, Cell Therapy Bioprocessing • AstraZeneca

Giovanni Lorenzon

Bioprocess Specialist • Eppendorf

Marcos Langtry

Director of Commercial Development, Allogeneic Cell Therapy • Lonza Ltd

Event Info


2022 Spotlight Roundtables

Take a look at the 2022 sample attendee list for Advanced Therapies Europe here.

Pub & Pints RSVP

Let us know you’re planning on attending.